(Q44749272)

5 December 2017

Viral features of lamivudine resistant hepatitis B genotypes A and D. (English)

1 reference

Elisabeth Puchhammer-Stöckl

5 December 2017

1 reference

1 reference

3

object named as

Elisabeth Puchhammer-Stöckl

1 reference

5 December 2017

Bernhard Zöllner

1

1 reference

5 December 2017

Jörg Petersen

2

1 reference

5 December 2017

Josef Kletzmayr

4

1 reference

5 December 2017

Martina Sterneck

5

1 reference

5 December 2017

Lutz Fischer

6

1 reference

5 December 2017

Matthias Schröter

7

1 reference

5 December 2017

Rainer Laufs

8

1 reference

5 December 2017

Heinz-Hubert Feucht

9

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

5 December 2017

1 reference

5 December 2017

39

1 reference

5 December 2017

1

1 reference

5 December 2017

42-50

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

5 December 2017

1 reference

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences

21 January 2018

1 reference

Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy

21 January 2018

1 reference

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

Clinical impact of lamivudine resistance in chronic hepatitis B.

21 January 2018

1 reference

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy

21 January 2018

1 reference

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment

21 January 2018

1 reference

20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.

21 January 2018

1 reference

Hepatitis B genotypes and the response to interferon therapy

21 January 2018

1 reference

High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system

21 January 2018

1 reference

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

MEGA2: molecular evolutionary genetics analysis software

21 January 2018

1 reference

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

21 January 2018

1 reference

In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy - a clinical note

21 January 2018

1 reference

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance

21 January 2018

1 reference

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library

21 January 2018

1 reference

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

21 January 2018

1 reference

Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients

21 January 2018

1 reference

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

21 January 2018

1 reference

Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity

21 January 2018

1 reference

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

21 January 2018

1 reference

Primary infection with a lamivudine-resistant hepatitis B virus

21 January 2018

1 reference

Lamivudine as initial treatment for chronic hepatitis B in the United States

21 January 2018

1 reference

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

7 January 2021

1 reference

7 January 2021

Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains

1 reference

7 January 2021

Genetic variability in hepatitis B viruses

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20016

1 reference

5 December 2017

1 reference